Estudio de fase II, doble ciego, aleatorizado y controlado con placebo para determinar el efecto antiviral, la seguridad y la farmacocinética de la administración una vez al día durante 12 ó 24 semanas de BI 201335 NA, junto a la administración de interferón pegilado? 2a y ribavirina en pacientes con hepatitis C de genotipo 1 no tratados previamente.Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-? 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).

Boehringer Ingelheim España, S.A.0 sites420 target enrollmentAugust 4, 2008

Conditionsinfección crónica por el virus de la hepatitis C del genotipo 1chronic hepatitis C infection of genotype 1

DrugsPegasys Copegus 200mg

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: infección crónica por el virus de la hepatitis C del genotipo 1chronic hepatitis C infection of genotype 1
Sponsor: Boehringer Ingelheim España, S.A.
Enrollment: 420
Status: Active, not recruiting
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

August 4, 2008

End Date

November 28, 2011

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Boehringer Ingelheim España, S.A.

Eligibility Criteria

Inclusion Criteria

•1\)Chronic hepatitis C infection, diagnosed by seropositivity for anti\-HCV antibodies or detectable HCV RNA at least 6 months prior to screening
•2\)HCV infection of genotype 1(1a, 1b or mixed 1a/1b) diagnosed by genotypic testing or screening
•3\)Therapy\-naive to interferon (including any experimental or investigational interferon products as monotherapy or in combination with any other agents), pegylated interferon, or ribavirin for acute or chronic hepatitis C infection
•4\)HCV viral load\>\=100\.000 IU/mL at screening
•5\) Exclusion of liver cirrhosis by fibroscan or liver biopsy wihtin 24 months prior to study enrolment
•6\)Age 18 to 65
•7\)Female patients (a)with documented hysterectomy, or (b) who have had both ovaries removed, or (c) with documented tubal ligation, or (d) who are post\-menopausal with last menstrual period at least 12 months prior to screening, or
•(e) childbearing potenital with a negativ serum pregnancy test at screening and on Day 1 (Visit 2\) that either agree to abstain from intercourse, or agree to use one of the appropriate medically accepted methods of birth control (see below) from the date of scrreening until 6 months after the last dose of ribavirin in addition to the consistent and correct use of a condom, and that are not breats\-feeding or nursing or plan to nurse at any time from the date of screening until 6 months after the last dose of ribavirin.
•Note : Pregnancy tests must be performed every 4 weeks after screening until 6 months after the last dose of ribavirin for females of childbearing potential. Note: Medically accepted methods of contraception for females in this trial are ethinyl estradiol containing contraceptives, diaphragm with spermicide substance, and cervical cap.
•8\)Male patients (a) who are documented to be sterile, or (b) who agree to abstain from intercourse from the date of screening until 6 months after the last dose of ribavirin, or (c) who consistently and correctly use a condom while their female partners (if applicable) agree to use one of the appropriate medically accepted methods of birth control (see below) fro mthe date of screening until 6 months after the last dose of ribavirin, and (d) without pregnant female partners. It is in the responsibility of the male patient to ensure that his partner (or partners) is not pregnant prio to entry into the study or becomes pregnant during the treatment and follow\-up phase. Female partners of childbearing potential must agree to perform a monthly pregnancy test from the date of screening until 6 months after the last dose of ribavirin

Exclusion Criteria

•1\)Hepatitis C infection of mixed genotype diagnosed by genotypic testing at screening
•2\)Patients who have been previously treated with at least one dose of any protease inhibitor for acute or chronic hepatitis C infection
•3\)Evidence of liver disease due to causes other than chronic HCV infection
•4\)Positive ELISA for HIV\-1 or HIV\-2
•5\) Hepatitis B virus (HBV) infection based on presence of HBs\-Ag
•6\) Decompensated liver disease, or history of decompensated liver disease, as evidenced by ascites, portal hypertension, jaundice or hepatic encephalopathy, coagulopathy, varices, history of variceal bleeding, or any other clincial evidence of decompensation
•7\) Active or suspected malignancy or history of malignancy within the last 5 years (with the exception of appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
•8\)History of alcohol or drug abuse within the past 12 months. Patients with documented drug and alcohol addiction free history of at least 12 months who are, in the opinion of the investigator, unlikely to relapse, may be enrolled in the study.
•Note: Patients with a positive drug screen other than cannabis at time of screening will be excluded from the trial.
•9\)Usage of any investigational drugs within 30 days prior to enrolment, or 5 half\-lives, whichever is longer; or the planned usage of an investigational drug during the course of the current study